Effects of dual antiplatelet therapy de-escalation on the prognosis of acute coronary syndrome patients at high risk of ischemia who underwent percutaneous coronary intervention  

作　　者：Jingyao Wang Yachao Li Mengjie Lei Yanli Yang Haiyan Gao Xiangjin Wang Lei An Haili Zhou Xue Sun Cairong Li Zhigang Zhao Zengming Xue 

机构地区：[1]Department of Cardiology,Langfang People’s Hospital,Hebei Medical University,Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease,Langfang,Hebei 065000,China

出　　处：《Chinese Medical Journal》2024年第6期746-748,共3页中华医学杂志（英文版）

基　　金：supported by the Self-financing Project of Lang Fang Science and Technology Research and Development Plan(Nos.2022013038 and 2020013106);Guiding Project of Hebei Medical Science Research Program(No.20232053)

摘　　要：To the Editor:Current guidelines recommend that for patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI),dual antiplatelet therapy(DAPT),preferably involving powerful P2Y_(12) receptor inhibitors,including ticagrelor or prasugrel,should be used for at least 12 months.^([1–3])However,there is a lack of relevant evidence regarding the feasibility of de-escalation treatment and specific DAPT treatment regimens for ACS patient populations with high ischemic risk.

关 键 词：CORONARY PATIENTS ACUTE 

分 类 号：R541.4[医药卫生—心血管疾病]